Show simple item record

dc.contributor.authorFriedlander, Men_US
dc.contributor.authorBanerjee, Sen_US
dc.contributor.authorMileshkin, Len_US
dc.contributor.authorScott, Cen_US
dc.contributor.authorShannon, Cen_US
dc.contributor.authorGoh, Jen_US
dc.coverage.spatialAustraliaen_US
dc.date.accessioned2017-04-06T11:18:41Z
dc.date.issued2016-12en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/27917619en_US
dc.identifier.citationAsia Pac J Clin Oncol, 2016, 12 (4), pp. 323 - 331en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/564
dc.identifier.eissn1743-7563en_US
dc.identifier.doi10.1111/ajco.12636en_US
dc.description.abstractOlaparib is the first oral poly(ADP-ribose) polymerase inhibitor to be approved as maintenance monotherapy for treatment of patients with platinum-sensitive relapsed BRCA-mutated (BRCAm) serous ovarian cancer. This review provides practical guidance on the use of olaparib (capsule formulation) in the maintenance setting. The article focuses on the key toxicities that can arise with olaparib therapy and recommendations for their management. Nausea, vomiting, fatigue and anemia are the most commonly reported adverse events in olaparib clinical trials and are generally mild to moderate and transient in nature in most patients. Implementation of an effective and timely management plan can control many of the side effects. It is vital that health care providers effectively communicate the potential side effects of olaparib, as well as educate patients on management strategies to combat these symptoms. To this end, realistic expectations regarding the potential side effects need to be set, with an understanding that dose interruptions and modifications may be required to allow patients to continue receiving treatment.en_US
dc.format.extent323 - 331en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectolapariben_US
dc.subjectovarian canceren_US
dc.subjectpractical guidanceen_US
dc.subjectside effectsen_US
dc.subjecttoxicityen_US
dc.subjectAntineoplastic Agentsen_US
dc.subjectFemaleen_US
dc.subjectHumansen_US
dc.subjectMutationen_US
dc.subjectNeoplasm Recurrence, Localen_US
dc.subjectOvarian Neoplasmsen_US
dc.subjectPhthalazinesen_US
dc.subjectPiperazinesen_US
dc.titlePractical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer.en_US
dc.typeJournal Article
dcterms.dateAccepted2016-09-22en_US
rioxxterms.versionofrecord10.1111/ajco.12636en_US
rioxxterms.licenseref.startdate2016-12en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfAsia Pac J Clin Oncolen_US
pubs.issue4en_US
pubs.notesNo embargoen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume12en_US
pubs.embargo.termsNo embargoen_US
dc.contributor.icrauthorBanerjee, Susanaen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/